"We see a greater reduction in cardiovascular events from intensive blood glucose control than from drugs that lower blood pressure and cholesterol," said Saul Genuth, M.D, of Case Western University. Genuth chairs the follow-up study of DCCT participants, called the Epidemiology of Diabetes Interventions and Complications (EDIC) study, which is examining the long-term effects of prior intensive versus conventional blood glucose control. "The benefits of intensive control strongly reinforce the message that this therapy should begin as early as possible and be maintained as long as possible."
"The risk of heart disease is about 10 times higher in people with type 1 diabetes than in people without diabetes," added David Nathan, M.D., of Massachusetts General Hospital, who co-chairs the study. "Maintaining tight control is difficult, but its advantages are huge. Intensive glucose control significantly reduces heart disease as well as damage to the eyes, nerves, and kidneys of people with type 1 diabetes. The longer we follow patients, the more we're impressed by the lasting benefits of tight control."
The DCCT results, announced in 1993, clearly showed that intensive glucose control prevents or delays the eye, nerve, and kidney complications of type 1 diabetes. However, researchers had not followed participants long enough to know whether tight control also lowered the risk of heart a
'"/>
Contact: Joan Chamberlain
niddkdkocpl@niddk.nih.gov
301-496-3583
NIH/National Institute of Diabetes and Digestive and Kidney Diseases
21-Dec-2005